Bexxar (Tositumomab, Iodine-131 Tositumomab) Can Be Safely Administered in Relapsed Low-Grade or Transformed Low-Grade Non-Hodgkin’s Lymphoma Patients After Prior Treatment With Rituximab: Initial Experience From the Expanded Access Study

OncologyONCOLOGY Vol 14 No 3
Volume 14
Issue 3

Tositumomab/iodine-131 tositumomab (Bexxar) is a new radioimmunotherapy for relapsed and refractory low-grade and transformed low-grade non-Hodgkin’s lymphoma (NHL). Iodine-131 tositumomab is a radiolabeled murine immunoglobulin

Tositumomab/iodine-131 tositumomab (Bexxar) is a new radioimmunotherapy for relapsed and refractory low-grade and transformed low-grade non-Hodgkin’s lymphoma (NHL). Iodine-131 tositumomab is a radiolabeled murine immunoglobulin G2a (IgG2a) monoclonal antibody directed against the CD20 antigen. With the availability of two monoclonal antibodies (tositumomab and rituximab [Rituxan]) containing murine protein and both directed against the CD20 antigen, it is important to establish the safety of using tositumomab in rituximab-treated patients.

As of April 8, 1999, 30 patients enrolled in the expanded access study had previously received treatment with rituximab. At study entry, 21 (70%) of 30 patients had low-grade NHL and 9 (30%) had transformed low-grade lymphoma. Patients had received a median of three (range, one to nine) prior chemotherapy regimens.

Baseline patient characteristics included: a median age of 57 years; 16 male patients; and a median time from diagnosis of 59 months. Of the 30 patients, 27 (90%) had stage III or IV disease; median International Prognostic Index (IPI) at study entry was 3.0; 20 (67%) patients had elevated lactic dehydrogenase (LDH); and 14 (47%) patients had a tumor diameter ³ 5 cm. Ten patients had positive bone marrow biopsies with < 25% lymphoma involvement.

All patients received a saturated solution of potassium iodide or Lugol’s solution and a single dosimetric dose (450 mg of tositumomab intravenously [IV] over 1 hour, followed by 35 mg of tositumomab radiolabeled with 5 mCi of iodine-131 over ½ hour) and then had three whole-body counts obtained over the next 7 days. The whole-body counts were used to calculate the required activity (mCi) to deliver the desired therapeutic dose (65 cGy for platelet counts of 100,000 to 149,999 cells/mm³ and 75 cGy for platelets ³ 150,000 cells/mm³). Twenty-eight patients received a single therapeutic dose (450 mg of tositumomab IV over 1 hour, followed by 35 mg of tositumomab containing an appropriate activity [mCi] of iodine-131 to deliver the specified total body dose [cGy] over 1/2 hour) 7 to 14 days after the dosimetric dose.

Two patients experienced transient grade 1 adverse events during the dosimetric infusion, and no patient required infusion rate adjustments. Median duration of the tositumomab predose infusion during the dosimetric dose was 1.0 hour (range, 1.0 to 1.1 hour).

Two patients did not receive the therapeutic infusion because of progressive NHL. No patient experienced an adverse event during the therapeutic infusion or required an adjustment or discontinuation of this infusion.

One patient was positive for human antimouse antibody (HAMA) at the time of study entry and was treated without complications. Two patients have developed HAMA reactions following treatment with tositumomab.

CONCLUSION: Tositumomab has been safely administered to patients with relapsed, low-grade or transformed, low-grade NHL who had been treated previously with rituximab.

Click here for Dr. Bruce Cheson’s commentary on this abstract.

Articles in this issue

Comparative Economic Analysis of the Treatment of Relapsed Low-Grade B-Cell Non-Hodgkin’s Lymphoma (NHL) in France Using CHOP, Fludarabine, or Rituximab
FHIT Gene, Smoking, and Cervical Cancer
Final Report on the Safety and Efficacy of Retreatment With Rituximab for Patients With Non-Hodgkins Lymphoma
Prospective, Randomized, Controlled Study of Zevalin Radioimmunotherapy Compared to Rituximab Immunotherapy for B-Cell, Non-Hodgkins Lymphoma: Interim Results
IOM Medical Error Estimates Questioned, But Legislation Considered
Less Toxic Therapies for Hodgkin’s Disease May Reduce Secondary Cancers
Preserving Fertility in Young Women With Ovarian Cancer Does Not Decrease Survival
Iodine-131 Tositumomab for Patients With Transformed, Low-Grade Non-Hodgkin’s Lymphoma: Overall Clinical Trial Experience
Survival Rates Significantly Worse For African-Americans With Endometrial Cancer
Rituximab Has Significant Activity in Patients With Chronic Lymphocytic Leukemia
Responders to Rituximab Show Continued Tumor Regression Over Time and a Progression-Free Survival That Correlates With Response Classification
PhRMA Criticizes FDA’s Proposed Rule on Antibiotic Approvals
Phase II Study of Rituximab in Combination With CHOP in Patients With Previously Untreated Intermediate- or High-Grade Non-Hodgkin’s Lymphoma
New Antibiotic Effective in Treating Gram-Positive Bacteremia
Reduced-Dose Zevalin Radioimmunotherapy for Relapsed or Refractory B-Cell Non-Hodgkin&#146;s Lymphoma Patients With Preexisting Thrombocytopenia: Report of Interim Results of a Phase II Trial
Related Videos
Experts on colorectal cancer
Arvind Dasari, MD, MS, an expert on colorectal cancer
Ashley E. Rosko, MD, specializes in multidisciplinary care for elderly patients with multiple myeloma, and how to make treatment most accessible to them.
At first relapse, novel therapies are offered to patients with multiple myeloma at The Ohio State University Comprehensive Cancer Center-The James.
Ashley E. Rosko, MD, highlights potential changes on the horizon to the standard of care in multiple myeloma therapy, and discussed the personalization of treatment based on transplant eligibility.
Experts on multiple myeloma
Expert on prostate cancer
Experts on multiple myeloma
MRD Tracking May Allow More ‘Individualized’ Management of Multiple Myeloma
Related Content